Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Table 2 Response rates of HCC to thalidomide

Author	n	Tumor response, n (%)
		CR1	PR2	SD3	PD4	CR1 + PR2 + SD3
Kong et al[14]	11	0	1 (9)	4 (36)	6 (55)	5 (46)
Lin et al[15]	27	0	1 (4)	1 (4)	25 (93)	2 (7)
Feun et al[16]	7	0	0	0	7 (100)	0
Schwartz et al[17]	30	1 (3)	1 (3)	9 (30)	19 (63)	11 (37)
Hsu et al[18]	63	1 (2)	3 (5)	20 (32)	39 (62)	24 (38)
Wang et al[19]	99	0	6 (6)	-	-	-
Chiou et al	42	0	2 (5)	9 (21)	31 (74)	11 (26)

¹Complete response;

²Partial response;

³Stable disease;

⁴Progressive disease.